ROCHESTER, NY and DUBAI, UAE, Feb. 17, 2023 – On March 1, Resiliélle Cosmetics, LLC and Regenerelle Biotherapeutics will unveil their new Resiliélle brand topical exosome cosmetics product manufactured by Regenerelle and exclusively distributed worldwide by Resiliélle. Resiliélle’s product will set a new standard for skin rejuvenation and lustrous hair. For optimal results, aesthetics professionals may use Resiliélle topically after microneedling or laser treatments. Resiliélle believes that the use of our topical exosome cosmetics will allow MedSpa, Dermatology and Plastic Surgery patients to use Resiliélle topical exosome cosmetics that have been developed to help patients to Leap Back In Time™ — At Any Age.™ [Read more…]
Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors
FUKUOKA, Japan, and BORDEAUX, France / February 15th, 2023 – GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on the biomimetic C-Stem™ technology platform, today announced they have entered into a collaboration for the expansion of donor-derived NK-like cells. [Read more…]
FDA Grants RMAT Designation for Rexlemestrocel-L in Chronic Low Back Pain
NEW YORK, Feb. 08, 2023 — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA) as delivery agent for injection into the lumbar disc. [Read more…]
Immunotherapy company iPSirius appoints Dr. Stephen Sullivan as Chief Operating Officer
iPSirius appoints COO to oversee human trials with allogeneic cancer vaccines made from stem cells
Paris, France, 10th February 2023 – iPSirius, a pre-clinical biotech company in the immuno-oncology field, is pleased to announce the appointment of a new COO, Dr. Stephen Sullivan. Dr. Sullivan, previously the program manager at the Global Alliance for iPSC therapies, is a pluripotent stem cell manufacturing expert. He will oversee the day-to-day operations of the company and the first in-human trials for the company’snovel therapeutic, IPVAC. [Read more…]
The Crowley Center for Regenerative & Biotherapeutics Names New Scientific Officer
Dr. Michael Heke, Ph.D. will drive integration of exosome-based topical cosmetics, regenerative biotherapeutics medical and scientific intelligence, and as well as aspects of patient safety as Managing Director-Scientific Officer.
Rochester, NY, February 8, 2023 — The Crowley Center™ for Regenerative & Biotherapeutics, LLC (aka AT Venture Center™, LLC) today announced that Dr. Heke has been appointed as Chief Scientific Officer of The Crowley Center, and its subsidiaries, Regenerelle™ Cellular & Exosome Biotherapeutics, Resiliélle™ Exosome Cosmetics, Sanatela® Regenerative Medical, Sanatela® AT Medical Solutions, Sanatela® Precision Cancer Diagnostics, Sanatela® Animal Biotechnologies, Sanatela® Biotechnologies, Sanatela® Matrix, Sanatela® Life Sciences and AT Venture Center for Global Techtrepreneurship™. Regenerelle’s and Sanatela’s IP technologies are both Patent Pending. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 80
- Next Page »
